Journal article
Co-Expression Networks Unveiled Long Non-Coding RNAs as Molecular Targets of Drugs Used to Treat Bipolar Disorder
TTT Truong, CC Bortolasci, B Spolding, B Panizzutti, ZSJ Liu, S Kidnapillai, M Richardson, L Gray, CM Smith, OM Dean, JH Kim, M Berk, K Walder
Frontiers in Pharmacology | Published : 2022
Abstract
Long non-coding RNAs (lncRNAs) may play a role in psychiatric diseases including bipolar disorder (BD). We investigated mRNA-lncRNA co-expression patterns in neuronal-like cells treated with widely prescribed BD medications. The aim was to unveil insights into the complex mechanisms of BD medications and highlight potential targets for new drug development. Human neuronal-like (NT2-N) cells were treated with either lamotrigine, lithium, quetiapine, valproate or vehicle for 24 h. Genome-wide mRNA expression was quantified for weighted gene co-expression network analysis (WGCNA) to correlate the expression levels of mRNAs with lncRNAs. Functional enrichment analysis and hub lncRNA identificati..
View full abstractRelated Projects (2)
Grants
Awarded by Stanley Medical Research Institute
Funding Acknowledgements
& nbsp;This research was funded by National Health and Medical Research Council (NHMRC) Project Grant (1078928) and Centre of Research Excellence (1153607). MB is supported by a NHMRC Senior Principal Research Fellowship (1156072). OMD is an R.D. Wright Biomedical NHMRC Career Development Fellow (1145634) and has received grant support from the Brain and Behavior Foundation, Marion and EH Flack Trust, Simons Autism Foundation, Australian Rotary Health, Stanley Medical Research Institute, Deakin University, Brazilian Society Mobility Program, Lilly, NHMRC, Australasian Society for Bipolar and Depressive Disorders and Sevier. She has also received in-kind support from BioMedica Nutracuticals, NutritionCare and Bioceuticals.